Table 2 Baseline features of the included studies
Study | Location | Disease condition | Excision Design | Arm 1 | Arm 2 | Arm 3 | Mean follow up (month) | Recurrence definition |
|---|---|---|---|---|---|---|---|---|
Castañeda 2014 [23] | Mexico | Primary | CA | Beva | Pla | – | 12 | I |
Karalezli 2014 [24] | Turkey | Primary | CA | Beva | Pla | – | 28.9 | II |
Motarje 2015 [31] | Iran | Primary | BST | Beva | Pla | – | 12 | I |
Ozgurhan 2013 [27] | Turkey | Recurrent | CA | Beva | Pla | – | 6 | I |
Razeghinejad 2010 [25] | Iran | Primary | CA | Beva | Pla | – | 7.7 | III |
Razeghinejad 2013 [26] | Iran | Primary | CA | Beva | Pla | – | 6 | III |
Razeghinejad 2014 [34] | Iran | Primary | CA | Beva | Pla | – | 6 | I; III |
Shahin 2012 [35] | Egypt | Primary | CA | Beva | Pla | – | 8 | NA |
Shenasi 2011 [33] | Iran | Primary | BST | Beva | Pla | – | 9 | I |
Singh 2016 [32] | India | Primary | CA | Beva | Pla | – | 3 | Tseng’s criteria [8] |
Cardillo 1995 [36] | Brazil | No data | CA | MMC | Pla | – | 28 | II |
Junior 2008 [44] | Brazil | Recurrent | CA | MMC | Pla | – | 6 | I |
Ma 2005 [45] | Taiwan | Recurrent | AMT | MMC | Pla | – | 28.2 | I |
Mahar 1993 [16] | Arabia | Primary & Recurrent | BST | MMC | Pla | – | 3–36* | I |
Mutlu 1999 [41] | Turkey | Recurrent | CA | MMC | Pla | – | 15.8 | II |
Parra 1995 [46] | Spain | Primary | BST | MMC | Pla | – | 14.1 | I |
Pery 2006 [42] | Israel | Primary | CA | MMC | Pla | – | 25.3 | I |
Salman 2010 [43] | Saudi Arabia | Recurrent | AMT | MMC | Pla | – | NA | NA |
Chen 1995 [5] | USA | Primary | BST | MMC | Pla | – | 11 | I |
Gupta 2003 [39] | India | Primary & Recurrent | BST | MMC | Pla | – | 8.7 | II |
Lam 1998 [15] | Hong Kong | Primary & Recurrent | BST | MMC | Pla | – | 30.1 | III |
Singh 1990 [48] | USA | Primary & Recurrent | BST | MMC | Pla | – | 12.4 | NA |
Pery 1994 [47] | Israel | Advanced/Recurrent | BST | MMC | Pla | – | 8.6 | NA |
Fakhry 2011 [38] | egypt | Recurrent | CA | MMC | Pla | – | 12 | I |
Silva 2013 [49] | Brazil | No data | CA | 5-FU | Pla | – | 3 | I |
Maldonado 1995 [50] | Spain | Primary | BST | 5-FU | Pla | – | 12.3 | NA |
Viani 2011 [51] | Brazil | No data | CA | β-RT | Pla | – | 18 | I |
Mourits 2008 [52] | The Netherlands | Primary | BST | β-RT | Pla | – | 40 | I |
M 2013 [55] | Turkey | Primary | CA | Beva | MMC | – | 13.85 | NA |
Ozsutcu 2013 [57] | Turkey | Primary | CA | Beva | MMC | Pla | 9 | III |
Bekibele 2016 [56] | Nigeria | Primary | CA | 5-FU | Beva | – | 18.35 | II |
Bekibele 2012 [54] | Nigeria | No data | CA | MMC | 5-FU | – | 8 | I |
Kareem 2012 [53] | Iraq | Primary | BST | MMC | 5-FU | – | 18.8 | NA |
Pery1993 [11] | Israel | Advanced/Recurrent | BST | MMC | β-RT | – | 15.3 | NA |